XOMA Royalty Corporation (XOMA)
(Delayed Data from NSDQ)
$27.09 USD
-1.10 (-3.90%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $27.26 +0.17 (0.63%) 5:22 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Brokerage Reports
XOMA Royalty Corporation [XOMA]
Reports for Purchase
Showing records 1 - 20 ( 332 total )
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Target Boosted to $117; Corporate Model and Broad Valuation Look Just Makes Sense to Us
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
The Future Is Now as XOMA Adds More Assets Including Current Revenue Driver
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Slap Another Royalty on That PL With OJEMDA Approval
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
A Position of Shopping Strength and Royalty Growth; 2023 Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Creativity in Value Creation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Another Right Place, Right Time Transaction; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Our XOMA All Grown Up; Big Win for Cash Balance and Business Model; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for XOMA 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
3Q23 Results; Diverse Pipeline Supported by Growing Revenue; Shopping Continues; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Third Vabysmo Approval, A Day One Check, and A Strategic Move; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Third Indication For Vabysmo Seems Not Too Far Off; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Vabysmo Royalty Cash Flow Pushing Forward Nicely; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
2Q23 Results; Inbounds at Highest Levels as Royalties Grow; Target Upped to $74
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Near-Term Potential Royalty Addition Continues to Highlight Aggregation Model; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
IXINITY Reach Should Broaden and Hit XOMA''s Bottom Line; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
New Partner, More Royalties; Hematology Portfolio Expands With the Addition of IXINITY
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
2022 Results; Business Model Begins to Bear Fruit With Recent Asset Approval and Acquisition
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Check a Nice One Off the Shopping List; Organon to Drive Clinical Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
3Q22 Results; Royalties Start Flowing and Shopping Continues; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J